ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 172 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2015. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $13,000 | +85.7% | 279 | +68.1% | 0.00% | – |
Q3 2019 | $7,000 | -36.4% | 166 | 0.0% | 0.00% | – |
Q2 2019 | $11,000 | +57.1% | 166 | +67.7% | 0.00% | – |
Q1 2019 | $7,000 | +40.0% | 99 | 0.0% | 0.00% | – |
Q4 2018 | $5,000 | +400.0% | 99 | +330.4% | 0.00% | – |
Q2 2018 | $1,000 | 0.0% | 23 | 0.0% | 0.00% | – |
Q1 2018 | $1,000 | -99.3% | 23 | -99.3% | 0.00% | -100.0% |
Q4 2017 | $152,000 | +1069.2% | 3,273 | +1246.9% | 0.00% | – |
Q3 2017 | $13,000 | +333.3% | 243 | +465.1% | 0.00% | – |
Q2 2017 | $3,000 | -70.0% | 43 | -69.9% | 0.00% | – |
Q1 2017 | $10,000 | -16.7% | 143 | -10.1% | 0.00% | – |
Q4 2016 | $12,000 | +140.0% | 159 | +169.5% | 0.00% | – |
Q3 2016 | $5,000 | – | 59 | +883.3% | 0.00% | – |
Q2 2016 | $0 | – | 6 | 0.0% | 0.00% | – |
Q1 2016 | $0 | -100.0% | 6 | -50.0% | 0.00% | – |
Q4 2015 | $1,000 | 0.0% | 12 | 0.0% | 0.00% | – |
Q3 2015 | $1,000 | – | 12 | +50.0% | 0.00% | – |
Q3 2014 | $0 | – | 8 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |